New cancer drug EVT801 tested in humans for first time

NCT ID NCT05114668

Completed Disease control Sponsor: Kazia Therapeutics Limited Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested an experimental drug called EVT801 in 32 adults with advanced solid tumours that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose to use in future studies. Participants took EVT801 capsules by mouth daily.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EVT801 (an experimental drug taken orally as a capsule)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumours that have not responded to other therapies.
What could go wrong: This is a very early, small Phase 1 trial with only 32 participants. Its main goal is safety and dosing, not effectiveness. Many early-stage drugs do not go on to become approved treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm Neoplasm Metastasis renal cell carcinoma sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR, ADULT

Contacts and locations

Locations

Centre Léon Bérard

Lyon, 69373, France
Institut Universitaire du Cancer Toulouse - Oncopole

Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.